Safety assessments
Cancer
ADVERSE EVENT, CANCER
Safety was assessed by evaluation of AEs, serious AEs (SAEs), AEs of special interest (AESIs), physical examinations, vital signs, single 12-lead electrocardiograms (ECGs) and cardiac monitoring, clinical laboratory data, and ECOG performance. AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Safety was assessed from the date of first study drug administration to 37 days after the date of last study drug administration.